Immunovant, Inc. (IMVT)
NASDAQ:IMVT
Want to see IMVT full AI Analyst Report?
IMVT Stock Chart & Stats
$29.30
-$0.80(-3.25%)
At close: 4:00 PM EST
$29.30
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$14.32 - $36.29
Previous CloseN/A
Volume171.97K
Average Volume (3M)2.26M
Market Cap
$7.72B
Enterprise Value$6.22B
Total Cash (Recent Filing)$902.11M
Total Debt (Recent Filing)$72.00K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 12, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding205,308,910
10 Day Avg. Volume1,546,626
30 Day Avg. Volume2,263,671
Financial Highlights & Ratios
PEG Ratio-6.12
Price to Book (P/B)5.31
Price to Sales (P/S)0.00
P/FCF Ratio-11.12
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.21K
Enterprise Value/Ebitda-12.33
Forecast
1Y Price Target
$46.33Price Target Upside58.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt reduces refinancing and solvency risk and gives management flexibility to fund multi-year R&D programs. For a clinical-stage biotech, minimal leverage is a durable strength that lowers short-term liquidity pressure and preserves strategic optionality for partnerships or licensing.
Material Equity And Asset BaseExpanded equity and asset base provides a substantive funding cushion to support ongoing clinical trials and regulatory activities. This scale of balance-sheet resources sustains development runway longer than peers with smaller capital bases and enables meaningful business development or financing choices.
Focused FcRn-targeted PipelineA clear scientific focus on FcRn inhibition across multiple IgG-mediated diseases creates a coherent development strategy and potential platform value. Multi-indication development reduces single-product binary risk and supports durable commercial optionality if one program achieves approval or attracts partners.
Bears Say
Pre-revenue StatusWithout operating revenue, the company depends on capital markets or deals to fund operations. This structural absence of product cash flow increases execution risk over months as clinical milestones and approvals determine ability to transition to sustainable revenue generation.
Widening Net LossesRapidly increasing losses reflect a stepped-up expense base to support expanded development but weaken long-term profitability prospects absent approvals. Larger recurring deficits raise dilution and financing frequency risk, affecting strategic flexibility over the next several quarters.
Accelerating Negative Free Cash FlowEscalating free cash outflows signal materially higher funding needs and heighten reliance on external financing. Over a multi-month horizon this undermines cash runway, increases dilution risk, and could pressure program timelines or force prioritization among development programs.
Immunovant News
IMVT FAQ
What was Immunovant, Inc.’s price range in the past 12 months?
Immunovant, Inc. lowest stock price was $14.32 and its highest was $36.28 in the past 12 months.
What is Immunovant, Inc.’s market cap?
Immunovant, Inc.’s market cap is $7.72B.
When is Immunovant, Inc.’s upcoming earnings report date?
Immunovant, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were Immunovant, Inc.’s earnings last quarter?
Immunovant, Inc. released its earnings results on May 20, 2026. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.592 by -$0.138.
Is Immunovant, Inc. overvalued?
According to Wall Street analysts Immunovant, Inc.’s price is currently Undervalued.
Does Immunovant, Inc. pay dividends?
Immunovant, Inc. does not currently pay dividends.
What is Immunovant, Inc.’s EPS estimate?
Immunovant, Inc.’s EPS estimate is -0.6.
How many shares outstanding does Immunovant, Inc. have?
Immunovant, Inc. has 205,308,910 shares outstanding.
What happened to Immunovant, Inc.’s price movement after its last earnings report?
Immunovant, Inc. reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.592. Following the earnings report the stock price went up 35.261%.
Which hedge fund is a major shareholder of Immunovant, Inc.?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.33 (58.13% Upside)
$46.33 (58.13% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.87%
12-Months-Change
Fundamentals
Return on Equity
-68.16%
Trailing 12-Months
Asset Growth
23.19%
Trailing 12-Months
Company Description
Immunovant, Inc.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
IMVT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum driven by exceptionally strong Phase II brepocitinib data in cutaneous sarcoidosis, multiple fully enrolled studies and a solid cash position to fund upcoming registrational activity. Key operational highlights include the brepo NDA in dermatomyositis, fully enrolled 1402 D2T RA and mosliciguat PH‑ILD studies, and constructive legal progress ahead of a March jury trial. Offsetting risks are the small size and baseline imbalances of the CS Phase II study (creating uncertainty aboutPhase III translation), ongoing litigation and evidentiary motions, continued high operating spend and typical regulatory/development timing uncertainties. Overall, the positives (clinical wins, pipeline momentum, enrollment success and cash runway) materially outweigh the programmatic and legal uncertainties identified on the call.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$46.33
▲(58.13% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
57.08% Insiders
12.26% Mutual Funds
3.06% Other Institutional Investors
20.25% Public Companies and Individual Investors